Can WuXi AppTec’s Integrated Discovery Platform Power Oncology? WuXi AppTec’s integrated platform combines high-authority screening, pharmacology, and early assessment in a single end-to-end system.

Discover the emerging class of degrader-antibody conjugates – a modality that is drawing increasing interest from biotech ...

The global antibody drug conjugate (ADC) market size was valued at USD 13.51 billion in 2025 and is predicted to hit around ...

Drug discovery has long been defined by time, cost and uncertainty. Developing and optimising a single therapeutic antibody ...

Recently, artificial intelligence (AI ) company OpenProtein.AI announced its partnership with large pharmaceutical ...

Amazon Bio Discovery uses a library of biological foundational models to design and run antibody research experiments.

In the race of innovative drug R&D, whether for antibodies, peptides, or novel binding proteins, the efficiency of early-stage molecule discovery is always the key factor determining project success ...

80% year-over-year increase in human antibody drug candidates, with the two most advanced now in pivotal Phase 3 trials SAN DIEGO, CA / ACCESS Newswire / March 4, 2026 / Ablexis, LLC, a ...

Alloy Therapeutics, Inc. ("Alloy"), a biotechnology ecosystem company dedicated to democratizing access to cutting-edge drug discovery technologies, today announced an agreement with AbbVie to develop ...

AAX Biotech has partnered with evitria AG to expand access to its Opti-mAb® platform, enabling earlier integration of ...

Biointron, an antibody contract research organization, launched a new developability platform that helps drug developers identify manufacturing problems early, potentially saving millions by catching ...

At a Reuters conference earlier this year, Johnson & Johnson chief information officer Jim Swanson offered a striking number: ...